D
PURE Bioscience, Inc.
PURE
$0.0688
$0.013825.09%
D
Sell
2/25/2025Upgraded
PURE Bioscience, Inc. (PURE) was upgraded to D- from E+ on 2/25/2025 due to an increase in the volatility index.
PURE Bioscience, Inc. (PURE) was upgraded to D- from E+ on 2/25/2025 due to an increase in the volatility index.
E
Sell
2/7/2025Downgrade
PURE Bioscience, Inc. (PURE) was downgraded to E+ from D- on 2/7/2025 due to a decline in the volatility index.
PURE Bioscience, Inc. (PURE) was downgraded to E+ from D- on 2/7/2025 due to a decline in the volatility index.
D
Sell
1/23/2025Upgraded
PURE Bioscience, Inc. (PURE) was upgraded to D- from E+ on 1/23/2025 due to an increase in the volatility index.
PURE Bioscience, Inc. (PURE) was upgraded to D- from E+ on 1/23/2025 due to an increase in the volatility index.
E
Sell
1/8/2025Downgrade
PURE Bioscience, Inc. (PURE) was downgraded to E+ from D- on 1/8/2025 due to a decline in the solvency index and volatility index. The quick ratio declined from 0.88 to 0.79, and debt to equity increased from -1.03 to -1.
PURE Bioscience, Inc. (PURE) was downgraded to E+ from D- on 1/8/2025 due to a decline in the solvency index and volatility index. The quick ratio declined from 0.88 to 0.79, and debt to equity increased from -1.03 to -1.
D
Sell
11/12/2024Upgraded
PURE Bioscience, Inc. (PURE) was upgraded to D- from E+ on 11/12/2024 due to an increase in the total return index, valuation index and volatility index.
PURE Bioscience, Inc. (PURE) was upgraded to D- from E+ on 11/12/2024 due to an increase in the total return index, valuation index and volatility index.
E
Sell
3/14/2023Downgrade
PURE Bioscience, Inc. (PURE) was downgraded to E+ from D- on 3/14/2023 due to a decline in the volatility index and total return index.
PURE Bioscience, Inc. (PURE) was downgraded to E+ from D- on 3/14/2023 due to a decline in the volatility index and total return index.
D
Sell
2/23/2023Upgraded
PURE Bioscience, Inc. (PURE) was upgraded to D- from E+ on 2/23/2023 due to an increase in the volatility index and total return index.
PURE Bioscience, Inc. (PURE) was upgraded to D- from E+ on 2/23/2023 due to an increase in the volatility index and total return index.
E
Sell
2/8/2023Downgrade
PURE Bioscience, Inc. (PURE) was downgraded to E+ from D- on 2/8/2023 due to a decline in the total return index and volatility index.
PURE Bioscience, Inc. (PURE) was downgraded to E+ from D- on 2/8/2023 due to a decline in the total return index and volatility index.
D
Sell
2/1/2023Downgrade
PURE Bioscience, Inc. (PURE) was downgraded to D- from D on 2/1/2023 due to a decline in the total return index and volatility index.
PURE Bioscience, Inc. (PURE) was downgraded to D- from D on 2/1/2023 due to a decline in the total return index and volatility index.
D
Sell
12/15/2022Upgraded
PURE Bioscience, Inc. (PURE) was upgraded to D from D- on 12/15/2022 due to a major increase in the growth index. Earnings per share increased from -$0.0134 to -$0.0089, and total revenue increased 14.32% from $412 to $471.
PURE Bioscience, Inc. (PURE) was upgraded to D from D- on 12/15/2022 due to a major increase in the growth index. Earnings per share increased from -$0.0134 to -$0.0089, and total revenue increased 14.32% from $412 to $471.
D
Sell
10/28/2022Downgrade
PURE Bioscience, Inc. (PURE) was downgraded to D- from D on 10/28/2022 due to a noticeable decline in the growth index and total return index. Earnings per share declined from -$0.0086 to -$0.0134, EBIT declined 22.66% from -$759 to -$931, and total revenue declined 21.37% from $524 to $412.
PURE Bioscience, Inc. (PURE) was downgraded to D- from D on 10/28/2022 due to a noticeable decline in the growth index and total return index. Earnings per share declined from -$0.0086 to -$0.0134, EBIT declined 22.66% from -$759 to -$931, and total revenue declined 21.37% from $524 to $412.
D
Sell
8/12/2022Upgraded
PURE Bioscience, Inc. (PURE) was upgraded to D from D- on 8/12/2022 due to an increase in the growth index, total return index and volatility index. Total revenue increased 25.96% from $416 to $524, EBIT increased 19.26% from -$940 to -$759, and operating cash flow increased 3.33% from -$630 to -$609.
PURE Bioscience, Inc. (PURE) was upgraded to D from D- on 8/12/2022 due to an increase in the growth index, total return index and volatility index. Total revenue increased 25.96% from $416 to $524, EBIT increased 19.26% from -$940 to -$759, and operating cash flow increased 3.33% from -$630 to -$609.
D
Sell
6/8/2022Upgraded
PURE Bioscience, Inc. (PURE) was upgraded to D- from E+ on 6/8/2022 due to an increase in the volatility index and growth index. Earnings per share increased from -$0.0091 to -$0.008.
PURE Bioscience, Inc. (PURE) was upgraded to D- from E+ on 6/8/2022 due to an increase in the volatility index and growth index. Earnings per share increased from -$0.0091 to -$0.008.
E
Sell
1/31/2022Downgrade
PURE Bioscience, Inc. (PURE) was downgraded to E+ from D- on 1/31/2022 due to a noticeable decline in the total return index and volatility index.
PURE Bioscience, Inc. (PURE) was downgraded to E+ from D- on 1/31/2022 due to a noticeable decline in the total return index and volatility index.
D
Sell
12/16/2021Downgrade
PURE Bioscience, Inc. (PURE) was downgraded to D- from D on 12/16/2021 due to a noticeable decline in the growth index, volatility index and total return index. Total revenue declined 41.68% from $859 to $501, operating cash flow declined 39.81% from -$412 to -$576, and EBIT declined 9.2% from -$728 to -$795.
PURE Bioscience, Inc. (PURE) was downgraded to D- from D on 12/16/2021 due to a noticeable decline in the growth index, volatility index and total return index. Total revenue declined 41.68% from $859 to $501, operating cash flow declined 39.81% from -$412 to -$576, and EBIT declined 9.2% from -$728 to -$795.
D
Sell
11/9/2021Upgraded
PURE Bioscience, Inc. (PURE) was upgraded to D from E+ on 11/09/2021.
PURE Bioscience, Inc. (PURE) was upgraded to D from E+ on 11/09/2021.
E
Sell
11/8/2021Downgrade
PURE Bioscience, Inc. (PURE) was downgraded to E+ from D on 11/8/2021 due to a major decline in the growth index, solvency index and total return index. Operating cash flow declined 18.73% from -$347 to -$412, debt to equity increased from 0.06 to 0.07, and the quick ratio declined from 3.24 to 2.84.
PURE Bioscience, Inc. (PURE) was downgraded to E+ from D on 11/8/2021 due to a major decline in the growth index, solvency index and total return index. Operating cash flow declined 18.73% from -$347 to -$412, debt to equity increased from 0.06 to 0.07, and the quick ratio declined from 3.24 to 2.84.
D
Sell
6/16/2021Downgrade
PURE Bioscience, Inc. (PURE) was downgraded to D from C- on 6/16/2021 due to a significant decline in the efficiency index, total return index and valuation index. Net income declined 36.3% from -$595 to -$811, and total capital declined 7.97% from $4.51M to $4.15M.
PURE Bioscience, Inc. (PURE) was downgraded to D from C- on 6/16/2021 due to a significant decline in the efficiency index, total return index and valuation index. Net income declined 36.3% from -$595 to -$811, and total capital declined 7.97% from $4.51M to $4.15M.
C
Hold
5/3/2021Upgraded
PURE Bioscience, Inc. (PURE) was upgraded to C- from D+ on 5/3/2021 due to an increase in the valuation index and volatility index.
PURE Bioscience, Inc. (PURE) was upgraded to C- from D+ on 5/3/2021 due to an increase in the valuation index and volatility index.
D
Sell
3/19/2021Downgrade
PURE Bioscience, Inc. (PURE) was downgraded to D+ from C- on 3/19/2021 due to a decline in the efficiency index, total return index and volatility index. Net income declined 230.56% from -$180 to -$595, and total capital declined 7.28% from $4.86M to $4.51M.
PURE Bioscience, Inc. (PURE) was downgraded to D+ from C- on 3/19/2021 due to a decline in the efficiency index, total return index and volatility index. Net income declined 230.56% from -$180 to -$595, and total capital declined 7.28% from $4.86M to $4.51M.
C
Hold
3/8/2021Upgraded
PURE Bioscience, Inc. (PURE) was upgraded to C- from D+ on 3/8/2021 due to an increase in the valuation index.
PURE Bioscience, Inc. (PURE) was upgraded to C- from D+ on 3/8/2021 due to an increase in the valuation index.
D
Sell
2/19/2021Downgrade
PURE Bioscience, Inc. (PURE) was downgraded to D+ from C- on 2/19/2021 due to a significant decline in the growth index, total return index and volatility index. Earnings per share declined from $0.0152 to -$0.0021, EBIT declined 113.53% from $1.32M to -$179, and operating cash flow declined 110.87% from $1.83M to -$199.
PURE Bioscience, Inc. (PURE) was downgraded to D+ from C- on 2/19/2021 due to a significant decline in the growth index, total return index and volatility index. Earnings per share declined from $0.0152 to -$0.0021, EBIT declined 113.53% from $1.32M to -$179, and operating cash flow declined 110.87% from $1.83M to -$199.
C
Hold
10/29/2020Downgrade
PURE Bioscience, Inc. (PURE) was downgraded to C- from C on 10/29/2020 due to a substantial decline in the total return index.
PURE Bioscience, Inc. (PURE) was downgraded to C- from C on 10/29/2020 due to a substantial decline in the total return index.
C
Hold
10/9/2020Upgraded
PURE Bioscience, Inc. (PURE) was upgraded to C from D on 10/9/2020 due to a significant increase in the total return index, efficiency index and growth index. Operating cash flow increased 917.41% from -$224 to $1.83M, net income increased 179.49% from $473 to $1.32M, and EBIT increased 179.11% from $474 to $1.32M.
PURE Bioscience, Inc. (PURE) was upgraded to C from D on 10/9/2020 due to a significant increase in the total return index, efficiency index and growth index. Operating cash flow increased 917.41% from -$224 to $1.83M, net income increased 179.49% from $473 to $1.32M, and EBIT increased 179.11% from $474 to $1.32M.
D
Sell
3/16/2020Upgraded
PURE Bioscience, Inc. (PURE) was upgraded to D from E+ on 3/16/2020 due to a noticeable increase in the volatility index, total return index and growth index. Earnings per share increased from -$0.0144 to -$0.0083, and EBIT increased 41.33% from -$1.13M to -$663.
PURE Bioscience, Inc. (PURE) was upgraded to D from E+ on 3/16/2020 due to a noticeable increase in the volatility index, total return index and growth index. Earnings per share increased from -$0.0144 to -$0.0083, and EBIT increased 41.33% from -$1.13M to -$663.
E
Sell
12/18/2019Downgrade
PURE Bioscience, Inc. (PURE) was downgraded to E+ from D on 12/18/2019 due to a decline in the growth index, efficiency index and solvency index. EBIT declined 37.47% from -$822 to -$1.13M, net income declined 37.36% from -$819 to -$1.13M, and total revenue declined 35.07% from $613 to $398.
PURE Bioscience, Inc. (PURE) was downgraded to E+ from D on 12/18/2019 due to a decline in the growth index, efficiency index and solvency index. EBIT declined 37.47% from -$822 to -$1.13M, net income declined 37.36% from -$819 to -$1.13M, and total revenue declined 35.07% from $613 to $398.
D
Sell
3/7/2019Upgraded
PURE Bioscience, Inc. (PURE) was upgraded to D from E+ on 3/7/2019 due to a large increase in the growth index and efficiency index. Operating cash flow increased 58.4% from -$1.06M to -$441, EBIT increased 49.59% from -$2.56M to -$1.29M, and net income increased 49.49% from -$2.57M to -$1.3M.
PURE Bioscience, Inc. (PURE) was upgraded to D from E+ on 3/7/2019 due to a large increase in the growth index and efficiency index. Operating cash flow increased 58.4% from -$1.06M to -$441, EBIT increased 49.59% from -$2.56M to -$1.29M, and net income increased 49.49% from -$2.57M to -$1.3M.
E
Sell
12/14/2018Downgrade
PURE Bioscience, Inc. (PURE) was downgraded to E+ from D on 12/14/2018 due to a major decline in the solvency index, efficiency index and total return index. Net income declined 85.4% from -$1.38M to -$2.57M.
PURE Bioscience, Inc. (PURE) was downgraded to E+ from D on 12/14/2018 due to a major decline in the solvency index, efficiency index and total return index. Net income declined 85.4% from -$1.38M to -$2.57M.
D
Sell
6/14/2018Upgraded
PURE Bioscience, Inc. (PURE) was upgraded to D from D- on 6/14/2018 due to an increase in the growth index and efficiency index. Net income increased 16.53% from -$2.03M to -$1.69M, earnings per share increased from -$0.0298 to -$0.0249, and EBIT increased 14.54% from -$2M to -$1.71M.
PURE Bioscience, Inc. (PURE) was upgraded to D from D- on 6/14/2018 due to an increase in the growth index and efficiency index. Net income increased 16.53% from -$2.03M to -$1.69M, earnings per share increased from -$0.0298 to -$0.0249, and EBIT increased 14.54% from -$2M to -$1.71M.
D
Sell
3/15/2018Downgrade
PURE Bioscience, Inc. (PURE) was downgraded to D- from D on 3/15/2018 due to a substantial decline in the growth index, total return index and volatility index. Total revenue declined 11.42% from $464 to $411, operating cash flow declined 5.53% from -$1.03M to -$1.09M, and EBIT declined 5.24% from -$1.93M to -$2.03M.
PURE Bioscience, Inc. (PURE) was downgraded to D- from D on 3/15/2018 due to a substantial decline in the growth index, total return index and volatility index. Total revenue declined 11.42% from $464 to $411, operating cash flow declined 5.53% from -$1.03M to -$1.09M, and EBIT declined 5.24% from -$1.93M to -$2.03M.
D
Sell
10/27/2017Downgrade
PURE Bioscience, Inc. (PURE) was downgraded to D from D+ on 10/27/2017 due to a noticeable decline in the efficiency index, solvency index and valuation index. Total capital declined 47.62% from $2.46M to $1.29M, the quick ratio declined from 1.19 to 0.77, and net income declined 6.21% from -$1.74M to -$1.85M.
PURE Bioscience, Inc. (PURE) was downgraded to D from D+ on 10/27/2017 due to a noticeable decline in the efficiency index, solvency index and valuation index. Total capital declined 47.62% from $2.46M to $1.29M, the quick ratio declined from 1.19 to 0.77, and net income declined 6.21% from -$1.74M to -$1.85M.
D
Sell
6/9/2017Upgraded
PURE Bioscience, Inc. (PURE) was upgraded to D+ from D- on 6/9/2017 due to an increase in the efficiency index, volatility index and total return index.
PURE Bioscience, Inc. (PURE) was upgraded to D+ from D- on 6/9/2017 due to an increase in the efficiency index, volatility index and total return index.
D
Sell
3/3/2017Downgrade
PURE Bioscience, Inc. (PURE) was downgraded to D- from D on 3/3/2017 due to a decline in the total return index, valuation index and volatility index.
PURE Bioscience, Inc. (PURE) was downgraded to D- from D on 3/3/2017 due to a decline in the total return index, valuation index and volatility index.
D
Sell
10/28/2016Downgrade
PURE Bioscience, Inc. (PURE) was downgraded to D from C on 10/28/2016 due to a significant decline in the efficiency index, valuation index and growth index. Net income declined 2,363.33% from $30 to -$679, and operating cash flow declined 0.47% from -$1.27M to -$1.27M.
PURE Bioscience, Inc. (PURE) was downgraded to D from C on 10/28/2016 due to a significant decline in the efficiency index, valuation index and growth index. Net income declined 2,363.33% from $30 to -$679, and operating cash flow declined 0.47% from -$1.27M to -$1.27M.
C
Hold
6/10/2016Upgraded
PURE Bioscience, Inc. (PURE) was upgraded to C from C- on 6/10/2016 due to a major increase in the growth index and volatility index. Total revenue increased 128.98% from $176 to $403, earnings per share increased from -$0.1858 to -$0.02, and EBIT increased 34.09% from -$2.26M to -$1.49M.
PURE Bioscience, Inc. (PURE) was upgraded to C from C- on 6/10/2016 due to a major increase in the growth index and volatility index. Total revenue increased 128.98% from $176 to $403, earnings per share increased from -$0.1858 to -$0.02, and EBIT increased 34.09% from -$2.26M to -$1.49M.
C
Hold
6/3/2016Downgrade
PURE Bioscience, Inc. (PURE) was downgraded to C- from C on 6/3/2016 due to a significant decline in the volatility index and total return index.
PURE Bioscience, Inc. (PURE) was downgraded to C- from C on 6/3/2016 due to a significant decline in the volatility index and total return index.
C
Hold
3/9/2016Upgraded
PURE Bioscience, Inc. (PURE) was upgraded to C from D+ on 3/9/2016 due to a significant increase in the efficiency index, total return index and volatility index. Net income increased 286.6% from -$2.82M to -$10.9M.
PURE Bioscience, Inc. (PURE) was upgraded to C from D+ on 3/9/2016 due to a significant increase in the efficiency index, total return index and volatility index. Net income increased 286.6% from -$2.82M to -$10.9M.
D
Sell
3/11/2015Upgraded
PURE Bioscience, Inc. (PURE) was upgraded to D+ from D on 3/11/2015 due to a large increase in the growth index and solvency index. Total revenue increased 133.33% from $117 to $273.
PURE Bioscience, Inc. (PURE) was upgraded to D+ from D on 3/11/2015 due to a large increase in the growth index and solvency index. Total revenue increased 133.33% from $117 to $273.
D
Sell
2/17/2015Upgraded
PURE Bioscience, Inc. (PURE) was upgraded to D from D- on 2/17/2015 due to an increase in the valuation index.
PURE Bioscience, Inc. (PURE) was upgraded to D from D- on 2/17/2015 due to an increase in the valuation index.
D
Sell
1/30/2015Downgrade
PURE Bioscience, Inc. (PURE) was downgraded to D- from D on 1/30/2015 due to a decline in the valuation index, solvency index and total return index.
PURE Bioscience, Inc. (PURE) was downgraded to D- from D on 1/30/2015 due to a decline in the valuation index, solvency index and total return index.
D
Sell
1/8/2015Upgraded
PURE Bioscience, Inc. (PURE) was upgraded to D from D- on 1/8/2015 due to an increase in the valuation index.
PURE Bioscience, Inc. (PURE) was upgraded to D from D- on 1/8/2015 due to an increase in the valuation index.
D
Sell
12/24/2014Downgrade
PURE Bioscience, Inc. (PURE) was downgraded to D- from D on 12/24/2014 due to a decline in the volatility index.
PURE Bioscience, Inc. (PURE) was downgraded to D- from D on 12/24/2014 due to a decline in the volatility index.
D
Sell
11/14/2014Downgrade
PURE Bioscience, Inc. (PURE) was downgraded to D from D+ on 11/14/2014 due to a noticeable decline in the growth index, solvency index and valuation index. The quick ratio declined from 0.39 to 0.07, total revenue declined 49.04% from $261 to $133, and operating cash flow declined 30.67% from -$1.37M to -$947.
PURE Bioscience, Inc. (PURE) was downgraded to D from D+ on 11/14/2014 due to a noticeable decline in the growth index, solvency index and valuation index. The quick ratio declined from 0.39 to 0.07, total revenue declined 49.04% from $261 to $133, and operating cash flow declined 30.67% from -$1.37M to -$947.
OTC PK
03/14/2025 3:15PM Eastern
Quotes delayed
